Loading...
XTAE
CBI
Market cap12mUSD
Apr 07, Last price  
30.30ILS
1D
-4.42%
1Q
-16.53%
Jan 2017
-87.40%
IPO
-97.04%
Name

Clal Biotechnology Industries Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
45,696.48
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
-61.79%
Revenues
104k
-71.89%
1,404,0002,062,0001,339,0003,182,0004,745,0003,545,0009,067,0007,671,0003,452,00023,899,00025,417,00024,183,00043,461,00012,767,000113,293,00074,544,00076,961,000370,000104,000
Net income
-31m
L-49.71%
-57,137,000-15,442,000-44,557,000-83,042,00065,425,000350,868,00087,333,000-93,554,000-151,602,000-367,635,000-118,462,000-213,820,000-27,893,000-44,942,000-154,112,000109,027,000-89,583,000-61,740,000-31,051,000
CFO
-9m
L-85.58%
-17,434,000-23,549,000-47,049,000-52,415,000-86,860,000-111,926,000-102,451,000-81,222,000-148,976,000-115,952,000-146,999,000-112,633,000-91,405,000-86,981,00027,029,000-33,226,000-41,327,000-59,037,000-8,513,000
Dividend
Mar 29, 202122.3722 ILS/sh

Profile

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It invests between $0.5 million and $10 million per company. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel with an additional office in Cambridge, Massachusetts. It operates as a former subsidiary of Clal Industries and Investments Ltd.
URL
https://www.cbi.co.il/
IPO date
May 30, 2007
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
104
-71.89%
370
-99.52%
Cost of revenue
5,484
31,321
Unusual Expense (Income)
NOPBT
(5,380)
(30,951)
NOPBT Margin
Operating Taxes
107,778
113,953
Tax Rate
NOPAT
(113,158)
(144,904)
Net income
(31,051)
-49.71%
(61,740)
-31.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
222
23,694
BB yield
-0.36%
-24.05%
Debt
Debt current
5,441
1,850
Long-term debt
35,138
16,828
Deferred revenue
Other long-term liabilities
27,392
Net debt
(110,994)
(144,451)
Cash flow
Cash from operating activities
(8,513)
(59,037)
CAPEX
(5)
(1,273)
Cash from investing activities
7,655
(10,955)
Cash from financing activities
(1,180)
20,054
FCF
(104,781)
(140,064)
Balance
Cash
13,356
12,885
Long term investments
138,217
150,244
Excess cash
151,568
163,110
Stockholders' equity
(1,308,181)
(1,140,937)
Invested Capital
1,465,346
1,322,565
ROIC
ROCE
EV
Common stock shares outstanding
156,846
156,846
Price
0.40
-36.78%
0.63
-46.87%
Market cap
62,268
-36.78%
98,499
-47.40%
EV
(26,676)
(27,082)
EBITDA
(4,854)
(13,308)
EV/EBITDA
5.50
2.03
Interest
3,544
3,725
Interest/NOPBT